CAJ | 학술논문

目的观察口服替吉奥治疗老年晚期胃癌的疗效和不良反应.方法 23例老年进展期胃癌患者,口服替吉奥胶囊,40 ～60 mg/次,2次/d,连续服用4周,休息2周,6周为1个周期,2个周期后评价疗效和不良反应.结果 23例中完全缓解0例,部分缓解8例(34.7％)、稳定9例(34.7％)、进展6例(26.1％),有效率(完全缓解+部分缓解)为34.7％,肿瘤控制率(完全缓解+部分缓解+稳定)为73.9％.主要不良反应为骨髓抑制,胃肠道反应,色素沉着等.结论替吉奥是治疗进展期胃癌安全、有效的药物,特别适宜于老年体弱的患者.
목적 관찰구복체길오치료노년만기위암적료효화불량반응.방법 23례노년진전기위암환자,구복체길오효낭,40 ～60 mg/차,2차/d,련속복용4주,휴식2주,6주위1개주기,2개주기후평개료효화불량반응.결과 23례중완전완해0례,부분완해8례(34.7％)、은정9례(34.7％)、진전6례(26.1％),유효솔(완전완해+부분완해)위34.7％,종류공제솔(완전완해+부분완해+은정)위73.9％.주요불량반응위골수억제,위장도반응,색소침착등.결론 체길오시치료진전기위암안전、유효적약물,특별괄의우노년체약적환자.
Objective To evaluate the efficacy and toxicity of tegafur for elderly advanced gastric cancer.Methods Twenty-three elderly patients with advanced gastric cancer were treated with tegafur capsule 40-60 mg each time,two times perday.The evaluation of efficacy and toxicity were performed on all patients after 2 cycles.Results Of the 23 patients,there were 0 (0％) complete remission (CR),8 (34.7％) partial remission (PR),9 (34.7 ％) stable disease (SD) and 6 (26.1％) progression disease (PD).The total response rate (CR + PR) was 34.7％.The disease control rate(CR + PR + SD) was 73.9％.The major toxicities included myelo suppression,gastrointestinal reaction and cutaneous pigmentation.Conclusion Tegafur is safe and effective in the treatment of advanced gastric cancer,especially for old and frail patients.